Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors.

Authors

Karolina Dziadkowiec, HCA HealthcareFollow
Peter Stawinski, HCA HealthcareFollow
Jose Proenza

Division

East Florida

Hospital

JFK Medical Center

Document Type

Abstract

Publication Date

1-1-2021

Keywords

empagliflozin, diabetes mellitus, pancreatitis, drug-related side effects and adverse reactions

Disciplines

Endocrine System Diseases | Gastroenterology

Abstract

Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tract infections among others. We present a case of severe epigastric abdominal pain consistent with acute pancreatitis in the setting of empagliflozin use, suggesting a possible drug-induced acute pancreatitis.

Publisher or Conference

ACG Case Reports Journal

Recommended Citation

Dziadkowiec KN, Stawinski PM, Proenza J. Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors. ACG Case Rep J. 2021;8(1):e00530. Published 2021 Jan 19. https://doi.org/10.14309/crj.0000000000000530